During the past decade, St.Elisabeth-Krankenhaus Brustzentrum conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "St.Elisabeth-Krankenhaus Brustzentrum" are "Breast Cancer" (1 trials), "Metastatic Breast Cancer" (1 trials) and "Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "St.Elisabeth-Krankenhaus Brustzentrum" in a lesser frequency.

Most popular intervention types in "St.Elisabeth-Krankenhaus Brustzentrum" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abraxane" (1 trials), "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials) and "Nab-Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "St.Elisabeth-Krankenhaus Brustzentrum" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "St.Elisabeth-Krankenhaus Brustzentrum". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in St.Elisabeth-Krankenhaus Brustzentrum, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in St.Elisabeth-Krankenhaus Brustzentrum, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".